Merigolix (INNTooltip International Nonproprietary Name; developmental code names HS-10518, NCE-403, SKI-2670, TU-2670) is a gonadotropin releasing hormone (GnRH) antagonist which is under development for the treatment of endometriosis and uterine fibroids.

[1] The drug is being developed by TiumBio, Daewon Pharmaceutical, and Jiangsu Hansoh Pharmaceutical.

[1][2] As of October 2024, it is in phase 2 clinical trials for both endometriosis and uterine fibroids.

[1][2] This drug article relating to the genito-urinary system is a stub.

You can help Wikipedia by expanding it.